Clinical Trials Logo
  1. Home
  2. Hypercholesterolemia, Familial
  3. NCT00280995
  4. Details
NCT00280995 Clinical Trial

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial Clinical Trial

Official title:
A Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00280995
Other study ID # 301012CS8
Secondary ID EudraCT No.: 200
Status Completed
Phase Phase 2
First received January 20, 2006
Last updated August 1, 2016
Start date January 2006
Est. completion date August 2007

Study information
Verified date August 2016
Source Kastle Therapeutics, LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationNetherlands: Central Committee on Research Involving Human Subjects
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Homozygous Familial Hypercholesterolemia

Recruitment information / eligibility
Status Completed
Enrollment 12
Est. completion date August 2007
Est. primary completion date April 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Weight = 40 kg for Cohorts A, B, & C; Weight = 50 kg for Cohort D

- Diagnosis of Homozygous Familial Hypercholesterolemia.

- Female must be non-pregnant and non-lactating.

- On stable lipid lowering therapy for at least 4 weeks.

- Lipid values that meet the pre-specified criteria.

Exclusion Criteria:

- Subject had heart problems in the prior 6 months.

- Subject has elevated ALT, AST, or CPK.

- History of renal disease, liver disease, or malignancy.

- Use of oral anticoagulants, unless the dose has been stable for 4 weeks

- Have any other conditions, which in the opinion of the Investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in or completing the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• ISIS 301012
100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
• ISIS 301012
200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
• ISIS 301012
300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
• ISIS 301012
50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
Kastle Therapeutics, LLC Ionis Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Netherlands, 

Outcome
Type Measure Description Time frame Safety issue
Primary Percent reduction in LDL-cholesterol from baseline Week 7 (Cohorts A-C), Week 15 (Cohort D) No
See also
  Status Clinical Trial Phase
Terminated NCT00384293 - Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) Phase 3
Completed NCT04722068 - Regeneron 1331 Kinetics Sub-Study HoFH N/A
Completed NCT04118348 - Evaluating the Efficacy of Pediatric Lipid Screening Alerts N/A
Completed NCT00000594 - NHLBI Type II Coronary Intervention Study Phase 3
Completed NCT04526457 - Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia N/A
Completed NCT01753232 - Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter N/A
Completed NCT03018678 - Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
Completed NCT00134511 - Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder Phase 3
Completed NCT00134485 - Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia Phase 3
Recruiting NCT04073797 - PET Imaging of Inflammation and Lipid Lowering Study N/A
Terminated NCT01583647 - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Phase 1
Completed NCT00515307 - Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia Phase 1
Recruiting NCT04656028 - Genetic Testing and Motivational Counseling for FH N/A
Terminated NCT00092833 - Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) Phase 3
Active, not recruiting NCT04837638 - Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
Completed NCT06231459 - Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia Phase 4
Completed NCT01524289 - Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) Phase 3
Completed NCT00281008 - Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Recruiting NCT03989167 - Clinical Decision Support for Familial Hypercholesterolemia N/A
Completed NCT03795038 - Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI N/A